NEULANDLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | NEULANDLAB | Market Cap | 17,380 Cr. | Current Price | 13,538 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 89.2 | Book Value | 1,257 ₹ | Dividend Yield | 0.09 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 14,766 ₹ | DMA 200 | 14,387 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 96.5 Cr. | PAT Prev Qtr | 13.7 Cr. |
| RSI | 42.2 | MACD | -653 | Volume | 62,728 | Avg Vol 1Wk | 46,452 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.88 | Debt to equity | 0.16 |
| 52w Index | 35.9 % | Qtr Profit Var | 202 % | EPS | 187 ₹ | Industry PE | 29.0 |
📊 Chart & Trend Analysis:
NEULANDLAB is trading at ₹13,538, below both its 50 DMA (₹14,766) and 200 DMA (₹14,387), indicating short-term weakness. RSI at 42.2 suggests neutral-to-weak momentum, not yet oversold. MACD at -653 shows a strong bearish crossover, signaling downward bias. Bollinger Bands place price near the lower range, reflecting selling pressure. Current volume (62k) is slightly above the 1-week average (46k), showing moderate participation during the decline.
📈 Momentum Signals:
- RSI neutral, leaning bearish.
- MACD strongly negative, confirming short-term weakness.
- Price below both 50 & 200 DMA indicates bearish bias.
- Volume slightly above average, suggesting cautious trading activity.
🎯 Optimal Entry & Exit Zones:
- Entry Zone: ₹13,300 – ₹13,500 (near support levels).
- Exit Zone: ₹14,300 – ₹14,800 (resistance at 200 & 50 DMA).
- Stop Loss: ₹13,000 (below key support).
📌 Trend Status: The stock is reversing downward from recent highs, showing bearish bias and failing to sustain above resistance levels.
Positive
- Quarterly PAT surged to ₹96.5 Cr. from ₹13.7 Cr., showing strong earnings growth (+202%).
- EPS of ₹187 reflects a solid earnings base.
- ROCE (18.7%) and ROE (14.8%) highlight decent capital efficiency.
- FII holding increased (+0.30%) and DII holding increased (+1.17%), showing institutional confidence.
- Debt-to-equity ratio of 0.16 indicates manageable leverage.
Limitation
- High P/E (89.2) compared to industry average (29.0) suggests overvaluation.
- Dividend yield of 0.09% is negligible, limiting income appeal.
- Stock trading below both 50 DMA and 200 DMA reflects weak technical strength.
- 52-week index at 35.9% shows poor performance relative to highs.
Company Negative News
- MACD strongly negative, signaling bearish momentum.
- High valuation may limit upside in the near term.
Company Positive News
- Quarterly profit growth of 202% signals strong operational turnaround.
- Institutional support increased from both FII and DII investors.
Industry
- Industry P/E at 29.0 is far lower than NEULANDLAB’s P/E (89.2), suggesting relative overvaluation.
- Pharmaceutical sector remains resilient, supported by demand for APIs and specialty drugs.
Conclusion
⚖️ NEULANDLAB is reversing downward with bearish bias, trading below key moving averages and showing weak momentum. While fundamentals show strong quarterly profit growth and institutional support, stretched valuations and technical weakness limit upside. Short-term traders may consider entry near ₹13,300–₹13,500 with exits around ₹14,300–₹14,800, while long-term investors should wait for valuation correction and stronger technical confirmation before fresh accumulation.